EZH2 is associated with malignant behavior in pancreatic IPMN via p27 Kip1 downregulation

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Kuroki, Hideyuki ^a   Hayashi, Hiromitsu ^a   Okabe, Hirohisa ^a   Hashimoto, Daisuke ^a   Takamori, Hiroshi ^a   Nakahara, Osamu ^a   Nakagawa, Shigeki ^a   Fukushima, Yukiko ^a   Chikamoto, Akira ^a   Beppu, Toru ^a   Hirota, Masahiko ^b   Iyama, Ken Ichi ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; MESSENGER RNA; PARAFFIN; TRANSCRIPTION FACTOR EZH2; BMI1 PROTEIN; BMI1 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

AGED; ARTICLE; BENIGN TUMOR; CARCINOMA IN SITU; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; CANCER GRADING; CANCER STAGING; COLLOID CARCINOMA; DISEASE COURSE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PAPILLARY CARCINOMA; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84905474608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100904     Document Type: Article

References (29)

1. Kimura W, Nagai H, Kuroda A, Muto T, Esaki Y (1995) Analysis of small cystic lesions of the pancreas. Int J Pancreatol 18: 197-206. (Pubitemid 26023501)
2. Zhang XM, Mitchell DG, Dohke M, Holland GA, Parker L (2002) Pancreatic cysts: depiction on single-shot fast spin-echo MR images. Radiology 223: 547-553. (Pubitemid 34454341)
3. Izawa T, Obara T, Tanno S, Mizukami Y, Yanagawa N, et al. (2001) Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer 92: 1807-1817. (Pubitemid 32952499)
4. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, et al. (2004) Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 239: 788-797; discussion 797-789.
5. Yamao K, Ohashi K, Nakamura T, Suzuki T, Shimizu Y, et al. (2000) The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology 47: 1129-1134.
6. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, et al. (2001) Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 234: 313-321; discussion 321-312.
7. Raimondo M, Tachibana I, Urrutia R, Burgart LJ, DiMagno EP (2002) Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 97: 2553-2558.
8. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, et al. (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239: 678-685; discussion 685-677.
9. Fritz S, Warshaw AL, Thayer SP (2009) Management of mucin-producing cystic neoplasms of the pancreas. Oncologist 14: 125-136.
10. Lubezky N, Ben-Haim M, Marmor S, Brazowsky E, Rechavi G, et al. (2011) High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN). J Gastrointest Surg 15: 503-511.
11. Z'Graggen K, Rivera JA, Compton CC, Pins M, Werner J, et al. (1997) Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 226: 491-498; discussion 498-500.
12. Biankin AV, Biankin SA, Kench JG, Morey AL, Lee CS, et al. (2002) Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 50: 861-868. (Pubitemid 34539051)
13. Miyasaka Y, Nagai E, Yamaguchi H, Fujii K, Inoue T, et al. (2007) The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 13: 4371-4377. (Pubitemid 47219702)
14. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, et al. (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579-1588.
15. Puppe J, Drost R, Liu X, Joosse SA, Evers B, et al. (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 11: R63.
16. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, et al. (2012) 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 130: 2557-2567.
17. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, et al. (2012) TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res 18: 4201-4212.
18. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, et al. (2012) Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 78: 138-143.
19. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-1043. (Pubitemid 35247314)
20. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611. (Pubitemid 37205983)
21. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
22. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, et al. (2012) EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 26: 439-444.
23. Ougolkov AV, Bilim VN, Billadeau DD (2008) Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14: 6790-6796.
24. Fan T, Jiang S, Chung N, Alikhan A, Ni C, et al. (2011) EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression. Molecular cancer research : MCR 9: 418-429.
25. Wu J, Hu D, Yang G, Zhou J, Yang C, et al. (2011) Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J Cell Biochem 112: 1938-1948.
26. Song W, Tao K, Li H, Jin C, Song Z, et al. (2010) Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 101: 1754-1760.
27. Yoshizawa K, Nagai H, Sakurai S, Hironaka M, Morinaga S, et al. (2002) Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas. Virchows Arch 441: 437-443. (Pubitemid 35430457)
28. Sasaki S, Yamamoto H, Kaneto H, Ozeki I, Adachi Y, et al. (2003) Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep 10: 21-25.
29. Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T (1996) K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas 12: 362-368.